Herbalife's Aloin Identification Method for Aloe Vera Officially Recognized by AOAC INTERNATIONAL
LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced the Association of Official Analytical Collaboration (AOAC INTERNATIONAL) —a global authority in analytical science—has formally certified its proprietary method for identifying and measuring anthraquinones, also known as aloins, in aloe vera. Aloe regulatory groups require producers of ingestible aloe vera products to monitor naturally occurring compounds such as aloin A, aloin B, and aloe-emodin to meet safety guidelines. This certification officially recognizes Herbalife's longstanding method as the world's first AOAC-approved approach for detecting aloins—reinforcing safety and quality benchmarks across botanical and dietary supplement industries.
Developed by Herbalife scientists and validated by independent laboratories worldwide, this AOAC-certified method is used to test every batch of Herbalife's aloe-based products, ensuring safety, while preserving aloe vera's natural benefits. Aloe vera is a key ingredient in many of Herbalife's top products, which are sold in more than 90 markets.
'This AOAC validation is an important milestone for Herbalife and the industry as a whole,' said Gary Swanson, SVP of Global Quality at Herbalife and lead author of the study. 'We are proud to lead scientific innovation that enhances botanical ingredient safety, benefitting not only Herbalife products and our customers, but also advancing standards across the industry.'
Herbalife's method was validated through a global multi-laboratory study involving eight independent laboratories. Each lab tested the same set of six aloe vera samples, including both raw materials and finished products, using HPLC (High-Performance Liquid Chromatography) to measure aloin A, aloin B, and aloe-emodin. The study ensured the method's accuracy and reliability across various labs and product types, with results confirming that it met all performance criteria, including precision and system suitability.
'This multi-laboratory validation study supported approval of an analytical method developed by Herbalife scientists as the AOAC 2016.09 Official Final Action Method,' said Dr. Katerina Mastovska, deputy executive director and chief science officer, AOAC INTERNATIONAL. 'AOAC official methods undergo rigorous scientific evaluation and are highly credible and globally accepted. As such, this method will help strengthen botanical quality and safety standards worldwide.'
Herbalife has a long-standing commitment to aloe vera research and quality assurance. This dedication has resulted in five patents and three published studies focused on developing safe extraction methods that preserve the plant's natural benefits. While many companies rely solely on supplier certifications to confirm the authenticity of their aloe vera, Herbalife goes further. The company is one of the few in the world using advanced proton nuclear magnetic resonance (NMR) spectrometry—an analytical technique that uses magnetic fields and radio waves to identify the molecular structure of raw materials. This allows Herbalife to independently verify the identity and purity of its aloe vera at the molecular level, ensuring the highest standards of quality, consistency and traceability across its global supply chain.
For 45 years, Herbalife has upheld a global commitment to quality through its rigorous Seed to Feed process. This comprehensive system ensures that every ingredient—from responsibly sourced crops cultivated by dedicated farmers to the finished product—meets stringent standards for identity, potency, safety, and purity. Herbalife performs internal testing in ISO 17025-accredited laboratories, verifying that ingredients comply with both company standards and government regulations. The company's science-backed approach, grounded in Good Manufacturing Practices (GMPs) and NSF International standards, delivers consistent, transparent products in more than 90 markets. Supported by a global team of scientists and quality experts, this process strengthens consumer trust and continues to advance industry standards worldwide.
Herbalife's aloe vera testing method has been published in Journal of AOAC INTERNATIONAL (Volume 108, Issue 3, Pages 449-471).
About Herbalife Ltd.
Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life.
For more information, visit https://ir.herbalife.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Fatbeam Accelerates Market Expansion With Calix Broadband Platform, Targeting 2X Annual Growth in Home and MDU Subscribers
SAN JOSE, Calif.--(BUSINESS WIRE)-- Calix, Inc. (NYSE: CALX) announced today that fast-growing telecommunications provider Fatbeam —a leader in commercial and enterprise broadband—is embarking on a bold residential market expansion across southern Idaho. To fuel this transformation, Fatbeam has adopted the complete Calix Broadband Platform and integrated SmartLife ™ managed services to deliver secure, personalized experiences to single-family homes and multi-dwelling units (MDUs). Kicking off in the rapidly growing cities of Boise and Meridian, this expansion is part of Fatbeam's five-year growth strategy projected to double residential subscribers year-over-year. "This isn't just about building a network—it's about leveraging automation, innovation, and growth while creating lasting value for customers," said Danny Pate, chief operating officer at Fatbeam. To seize expansion opportunities across Idaho's coveted Treasure Valley neighborhoods, Fatbeam selected the Calix Platform for its unmatched power and flexibility. The Calix Platform equips broadband service providers (BSPs) with everything they need—from the access network to the subscriber premises. By unifying cloud analytics, network infrastructure, and managed services, the Calix Platform enables BSPs like Fatbeam to streamline operations, deliver personalized subscriber experiences, and lead with intelligence in every market—all while keeping the spotlight on the Fatbeam brand. 'Throughout my career, I've launched cloud platforms at multiple providers—and Calix is by far the best partner I've worked with,' said Danny Pate, chief operating officer at Fatbeam. 'The Calix Broadband Platform is unmatched, but what truly sets them apart is the full package: an end-to-end solution backed by a customer-centric support team that makes sustainable growth inevitable. From fiber-to-the-home to the most powerful subscriber app in the industry, Calix equips us to deliver world-class customer experiences, reduce subscriber churn, and scale faster. This isn't just about building a network—it's about leveraging automation, innovation, and growth while creating lasting value for customers.' Leveraging the complete Calix Platform and fully integrated SmartLife managed services, Fatbeam can: Supercharge subscriber acquisition with personalized campaigns that grow their brand. Advanced analytics from Calix Engagement Cloud and customizable creative assets from the Calix Market Activation program accelerate Fatbeam's market expansion. Automated, personalized outreach and assets like the Gerry Dee commercial series—recently shortlisted in The Drum Awards —help Fatbeam run campaigns that resonate with Idaho residents. Every asset is branded to Fatbeam, deepening subscriber engagement and trust. Deliver immediate value with secure, advanced experiences tailored to homes and MDUs. Every new residential Fatbeam subscriber will receive a Calix GigaSpire ® Wi-Fi system—pre-enabled with Protect IQ ® network-level cybersecurity, Experience IQ ® advanced parental controls, and Command IQ ® for intuitive in-app managed Wi-Fi that centers the Fatbeam brand. For seamless service delivery in MDUs, Fatbeam is leveraging the Unlimited Subscriber ™ portfolio to serve every resident in their footprint with exceptional experiences. Accelerate growth with proactive customer service that builds loyalty from day one. Fatbeam is equipping customer service representatives (CSRs) and field technicians with Calix Service Cloud and the Field Service App to deliver real-time insights and proactive support, starting at installation. By capturing rich service data, Fatbeam can resolve issues even before subscribers are impacted. The results are slashed truck rolls, boosted first-call resolution, and strengthened subscriber loyalty to support rapid growth. 'Strategic broadband leaders are investing in their communities for the long term,' said Michael Weening, president and chief executive officer at Calix. 'Fatbeam has a focus on growing a brand that wins markets. That is exactly why we innovated our cloud platform and managed services model. We give broadband service providers like Fatbeam everything they need to scale smarter and faster—providing deep analytics that help them get more ROI from their frontline teams and drive growth with advanced go-to-market precision. Danny has the right vision to lead this exciting transformation, and we will support them at every turn as they put subscriber experiences front and center. That is the winning playbook.' Watch the webinar replay, ' Beyond the Basics: Advanced Strategies for Optimizing the Customer Experience,' to discover how the Calix Broadband Platform powers experience-first growth for BSPs. About Calix Calix, Inc. (NYSE: CALX)—Calix is a platform, cloud, and managed services company. Broadband experience providers leverage Calix's broadband platform, cloud, and managed services to simplify their operations, subscriber engagement, and services; innovate for their consumer, business, and municipal subscribers; and grow their value for members, investors, and the communities they serve. Our end-to-end platform and managed services democratize the use of data—enabling our customers of any size to operate efficiently, acquire subscribers, and deliver exceptional experiences. Calix is dedicated to driving continuous improvement in partnership with our growing ecosystem to support the transformation of our customers and their communities. This press release contains forward-looking statements that are based upon management's current expectations and are inherently uncertain. Forward-looking statements are based upon information available to us as of the date of this release, and we assume no obligation to revise or update any such forward-looking statement to reflect any event or circumstance after the date of this release, except as required by law. Actual results and the timing of events could differ materially from current expectations based on risks and uncertainties affecting Calix's business. The reader is cautioned not to rely on the forward-looking statements contained in this press release. Additional information on potential factors that could affect Calix's results and other risks and uncertainties are detailed in its quarterly reports on Form 10-Q and Annual Report on Form 10-K filed with the SEC and available at Calix and the Calix logo are trademarks or registered trademarks of Calix and/or its affiliates in the U.S. and other countries. A listing of Calix's trademarks can be found at Third-party trademarks mentioned are the property of their respective owners.
Business Wire
an hour ago
- Business Wire
U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) approved ZUSDURI, the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC. ZUSDURI consists of mitomycin and sterile hydrogel, using UroGen's proprietary sustained release RTGel ® technology. ZUSDURI has been designed for potent tumor ablation. This landmark approval is based on the positive results from the Phase 3 ENVISION trial that demonstrated ZUSDURI delivers 78% complete response (CR) for patients at 3 months, and of those patients 79% remained event-free 12 months later. 'The approval of ZUSDURI represents a significant step forward for our company and for the treatment of recurrent LG-IR-NMIBC," said Liz Barrett, President and CEO of UroGen. "For the first time, the estimated 59,000 U.S. patients facing recurrent LG-IR-NMIBC each year have access to an FDA-approved medicine. This historic achievement is a bold leap forward in our mission to redefine uro-oncology and bring innovation to patients who need it most. We are deeply grateful to the FDA for their collaboration and to the investigators, patients, and caregivers whose commitment made this milestone possible. Their contributions have been essential in bringing meaningful innovation to the bladder cancer community.' The existing standard of care for LG-IR-NMIBC is a surgical procedure typically performed under general anesthesia called transurethral resection of bladder tumor (TURBT). Due to high recurrence rates of LG-IR-NMIBC, repeat TURBTs may be necessary. "ZUSDURI marks a breakthrough in uro-oncology, offering a new alternative for recurrent LG-IR-NMIBC patients who can live for many years with the disease but often endure multiple resections, under general anesthesia,' said Dr. Sandip Prasad, MD, Director of Genitourinary Surgical Oncology at Morristown Medical Center/Atlantic Health System, NJ, and principal investigator of the ENVISION trial. 'For decades, TURBT has been the standard approach for bladder cancer treatment. That's why innovative treatments like ZUSDURI are essential, especially for those adult patients with recurrent low-grade, intermediate-risk NMIBC.' The most common (≥ 10%) adverse reactions, including laboratory abnormalities, that occurred in patients were increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria. Serious adverse reactions occurred in 12% of patients who received ZUSDURI, including, urinary retention (0.8%) and urethral stenosis (0.4%). Product Availability ZUSDURI is expected to be available in the U.S. on or around July 1, 2025, for the treatment of adults with recurrent LG-IR-NMIBC. In the interim, patients can visit (available soon). UroGen Patient Support UroGen is committed to helping patients access ZUSDURI. UroGen Support may help identify appropriate financial assistance programs for eligible patients with commercial, Medicare or Medicaid coverage, as well as those with no insurance coverage. These programs are for eligible patients who have been prescribed ZUSDURI and who need help managing the cost of treatment. The appropriate program will depend on the patient's insurance coverage. Visit (available soon) or contact UroGen Support at 1-833-UROGEN-1 (1-833-876-4361) for additional information. Post-Marketing Commitment As a post-marketing commitment, UroGen has agreed with the FDA to complete the ongoing ENVISION trial to further characterize the clinical benefit of ZUSDURI for the treatment of patients with recurrent LG-IR-NMIBC. In addition, UroGen committed to provide the FDA annual updates on duration of response (DOR) for all patients with ongoing complete responses. The annual updates will continue until all ongoing patients experience a recurrence of LG-IR-NMIBC; progression; death; loss to follow-up; or reach 63 months after the first instillation as planned in the protocol, whichever occurs first. Conference Call & Webcast Information Members of UroGen's management team will host a live conference call and webcast on June 13, 2025 at 8:30 AM Eastern Time to review ZUSDURI approval details and commercialization plans. The live webcast can be accessed by visiting the Investors section of the Company's website at Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. An archive of the webcast will be available on the Company's website. About ZUSDURI ZUSDURI (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, approved for the treatment of adults with recurrent LG-IR-NMIBC. Utilizing UroGen's proprietary RTGel ® technology, a sustained release, hydrogel-based formulation, ZUSDURI is delivered directly into the bladder in an out-patient procedure by a trained healthcare professional using a urinary catheter to enable the treatment of tumors by non-surgical means. About Non-Muscle Invasive Bladder Cancer (NMIBC) LG-IR-NMIBC affects around 82,000 people in the U.S. every year and of those, an estimated 59,000 are recurrent. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include TURBT as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence, and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures. Learn more about non-muscle invasive bladder cancer at About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and ZUSDURI (mitomycin) for intravesical solution, UroGen's first product to treat recurrent LG-IR-NMIBC are both designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit to learn more or follow us on X, @UroGenPharma. APPROVED USE FOR ZUSDURI ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after previously receiving bladder surgery to remove tumor that did not work or is no longer working. IMPORTANT SAFETY INFORMATION You should not receive ZUSDURI if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI. Before receiving ZUSDURI, tell your healthcare provider about all of your medical conditions, including if you: have kidney problems are pregnant or plan to become pregnant. ZUSDURI can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI and for 6 months after the last dose. Males being treated with ZUSDURI: You should use effective birth control (contraception) during treatment with ZUSDURI and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ZUSDURI passes into your breast milk. Do not breastfeed during treatment with ZUSDURI and for 1 week after the last dose. How will I receive ZUSDURI? You will receive your ZUSDURI dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. During treatment with ZUSDURI, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving ZUSDURI: ZUSDURI may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. The most common side effects of ZUSDURI include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, and blood in your urine. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information. ZUSDURI ™ is a trademark and UroGen ® is a registered trademark of UroGen Pharma, Ltd. Copyright©2025 UroGen Pharma, Inc. All rights reserved. Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential benefits to patients and opportunities for ZUSDURI; the potential of UroGen's proprietary RTGel technology to improve therapeutic profiles of existing drugs other than mitomycin; and UroGen's sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as 'can,' 'expect,' 'may,' 'plan,' 'potential,' 'target,' 'will' or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen's industry; the scope, progress and expansion of developing and commercializing UroGen's products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen's ability to attract or retain key management, members of the board of directors and other personnel; UroGen's RTGel technology and ZUSDURI may not perform as expected; new data relating to ZUSDURI, including from spontaneous adverse event reports and from the ongoing ENVISION trial, may result in changes to the product label and may adversely affect sales, or result in withdrawal of ZUSDURI from the market; the potential for payors to delay, limit or deny coverage for ZUSDURI; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025. The events and circumstances discussed in such forward-looking statements may not occur, and UroGen's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.
Yahoo
an hour ago
- Yahoo
Why Oklo Stock Dropped on Thursday
Oklo stock needs to raise $460 million in new cash. The company will sell a lot of shares to do it. Oklo isn't expected to turn free cash flow positive for at least a decade. 10 stocks we like better than Oklo › Oklo (NYSE: OKLO) stock, one of a handful of new energy companies working to commercialize small modular nuclear reactor technology, tumbled more than 7% early Thursday morning before recovering to about a 1.3% loss as of 12:20 p.m. ET. The big dive early was sparked by an Oklo announcement last night, in which the company said it will create and sell $400 million worth of new shares of common stock (and potentially, up to $460 million shares if underwriters exercise their overallotment option). Oklo intends to use the money raised from this share offering "for general corporate purposes, working capital and capital expenditures, and potential future investments." This is another way of saying that Oklo doesn't make any money currently, and needs to sell shares to raise cash in order to fund its ongoing operations. The company didn't name any other specific use for the cash, such as buying another company. So Oklo is selling a lot of new stock. The question for investors is: Should you buy it? That really depends on how quickly you think Oklo can commercialize its business and begin generating cash on its own, so that it doesn't need to keep selling shares. Analysts polled by S&P Global Market Intelligence don't expect Oklo to begin generating any revenue at all until 2027, and forecast profitability won't arrive until 2030 -- five years in the future. Worse, they believe Oklo will still be burning cash (and needing to sell shares to remain solvent) through at least 2034 -- and probably longer than that. Call me a cynic, but if you ask me, a purchase of Oklo stock today isn't "investing" at all. It's speculating, pure and simple. Before you buy stock in Oklo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Oklo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor's total average return is 998% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Oklo Stock Dropped on Thursday was originally published by The Motley Fool
